Companies featured in this edition of the newsletter: ACTC, CHIP, CUR, CVM, ENZ, IMUC, IWEB, SRCO, SVUL, XSNX

Markets finally snapped their winning streak last week, as weakness in housing markets and durable goods orders led to broad-based declines in all of the major indices. All told, the Dow surrendered 155 points on the week to close at 9665, down 1.6% on the week but up 10.1% on the year. The Nasdaq lost 2.0% on the week to close at 2090, up 32.6% on the year, while the S&P 500 and Russell 2000 posted losses of 2.2% and 3.1% respectively, paring their yearly gains to 15.6% and 19.9%.

Unexpectedly poor data from the housing sector was the big economic story on the week as both new and existing August home sales failed to live up to expectations. New home sales increased modestly to 429,000, falling short of estimates calling

...

Companies featured in this edition of the newsletter: ACTC, CVM, CUR, DKAM, ENZ, IMUC, IWEB, PHC, SVUL, SRCO, SVUL, XSNX

Markets extended their winning streak yet again this week, as all ten sectors of the S&P 500 finished in positive territory and markets hit fresh highs for the year once again, despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow ended up 2.2% on the week, gaining 214 points to close at 9820 on the week, up 11.9% on the year. The Nasdaq performed slightly better, gaining 2.5% on the week, closing at 2132, up 35.2% on the year, while the S&P 500 and Russell 2000 gained 2.5% and 4.1% respectively, up 18.3% and 23.7% on the year.

While it was a relatively quiet week as far as headlines were concerned, there were some positive economic developments in the form

...

Neuralstem Inc. has patented technology which enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities. The company’s technology also has the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous systems diseases such as Amyotrophic Lateral Sclerosis (ALS), better known as Lou Gehrig’s disease.

The company announced today that the US Food & Drug Administration (FDA) has approved its investigational new drug application to commence a Phase 1 trial to treat ALS or Lou Gehrig’s disease with its spinal cord stem cells. Neuralstem is the first company to commence a stem cell trial to treat ALS. The disease affects roughly 30,000 people in the United States, with about 7,000 new diagnoses per year.

The trial will study the safety of Neuralstem’s cells and the

...

BrainStorm Cell Therapeutics Inc. has been gaining national recognition as a leading developer of adult stem cell technologies. Today, the company announced a major strategic agreement with Harlan Biotech Israel Ltd. (HBI) in order to complete pre-clinical safety experiments for the company’s innovative therapy for Amyotrophic Lateral Sclerosis (ALS), which is famously known as Lou Gehrig’s disease because it claimed the life of the famed baseball player.

This agreement will add to another agreement entered with PPS which was announced on August 31, 2009. Together, these agreements will allow the young company to complete the experiments required to submit an application to the Lelsinki Committee with the Israeli Ministry of Health for starting clinical trials for Lou Gehrig’s disease (ALS) in Israel.

Under the terms of the agreement with HBI, Harlan will perform pre-clinical safety experiments using the company’s cGMP compliant stem cells. The experiment will be performed immediately following production

...

Explore how Massachusetts General Hospital continues to shape modern medicine through our commitment to world-class medical care, research and education.

The MassGeneral Institute for Neurodegenerative Disease (MIND) is now poised to change the future for people with Alzheimer’s, ALS (Lou Gehrig’s), Huntington’s, Parkinson’s and other neurodegenerative diseases.

Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) recently announced the advance on-line publication of a clinical research paper entitled “Abnormal Serum Concentrations of Proteins in Parkinson’s Disease” in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson’s disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples.

About Transgenomic, Inc.

Transgenomic, Inc. (OTC BB: TBIO.OB, www.transgenomic.com ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation

...

 

PennyOmega.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From PennyOmega.com

________________________________________

 

Tuesday September 8, 2009

PennyOmega.com Stock Report!

**************************************************************

COPsync, Inc. (OTCBB:COYN), a software technology provider to law enforcement and emergency service professionals, announced today that Hill Country Software and Support, Inc. (HCSS) has entered into an Enterprise License Agreement with the Company.

RBC Life Sciences, Inc. (OTC Bulletin Board: RBCL), a provider of proprietary nutritional supplements and wound

...

BrainStorm Cell Therapeutics Inc. is a company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes.

BrainStorm Cell Therapeutics is currently focusing its technology on two diseases – Parkinson’s and ALS, which is also known as Lou Gehrig’s disease. The company announced today that it has entered into an agreement with Protein Production Services Ltd., a leading manufacturing contractor, in order to start “good manufacturing practice” production of its stem cell therapeutic product.

The clinical-grade product will be used in a pre-clinical safety trial for the company’s innovative therapy for Lou Gehrig’s disease. BrainStorm’s proprietary adult stem cell technologies have already been successfully tested on various animal models of neurodegenerative diseases. Neuro-protective and neuro-regenerative applications of the technology have been published in more than a dozen

...

Today, leading developer of adult stem cell technologies BrainStorm Cell Therapeutics Inc. announced that it has secured the necessary funding to complete pre-clinical trials for treatments of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The funding includes a prestigious grant from the Israeli government’s Office of the Chief Scientist (OCS) as well as a private investment.

CEO of BrainStorm, Rami Efrati, stated, “We are very gratified to receive these financial votes of confidence in our breakthrough stem cell technology. The new funding will enable us to complete our pre-clinical studies in ALS and meet our goal of beginning clinical studies in the coming year.”

The non-equity OCS grant totals $450,000 and marks the third consecutive year BrainStorm has received the award. Previously, the company received OCS grants totaling $798,000. BrainStorm’s royalty obligations to the OCS are capped at the amount of the grant received from the OCS.

Additionally, ACCBT

...

BSX, Boston Scientific Corporation

PWRM, Power 3 Medical Products Inc, PWRM.OB

PennyOmega.com Watch List!

PennyOmega.com Watch List ! for Tuesday July 21, 2009

Our Picks at PennyOmega.com for Tuesday July 21, 2009 are:

**************************************************************

BSX, Boston Scientific Corporation

BSX operates as a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties worldwide.

BSX’s products help physicians and other medical professionals improve the patients quality of life by providing alternatives to surgery.

*To consider about BSX

Today, after Closing Bell, BSX announced financial results for the second quarter ended June 30, 2009.

Net sales for the second quarter of 2009 were $2.074 billion, as compared to net sales of $2.024 billion for the second

...

Insmed Incorporated (Public, NASDAQ:INSM)broke $1 today, rising 13% to $1.02. We normally don't cover many penny stocks here at the Stockmasters, but Insmed has caught our eye as having a lot of potential. This is due to their news on IPLEX: The Food and Drug Administration is sharing with the public its decision to allow patients with Amyotrophic Lateral Sclerosis, a fatal neurodegenerative disease also known as Lou Gehrig's Disease, or ALS, to have access to a drug called Iplex under an Investigational New Drug ...